JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Iovance Biotherapeutics Inc

Closed

SectorHealthcare

3.11 -5.47

Overview

Share price change

24h

Current

Min

3.1

Max

3.21

Key metrics

By Trading Economics

Income

-38M

-116M

Sales

-24M

49M

Profit margin

-235.51

Employees

838

EBITDA

-35M

-110M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+197.12% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-337M

831M

Previous open

8.58

Previous close

3.11

News Sentiment

By Acuity

50%

50%

145 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jul 2025, 17:53 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 Jul 2025, 15:58 UTC

Earnings
Major Market Movers

Aon Shares Rise After 2Q Earnings Beat

25 Jul 2025, 15:08 UTC

Major Market Movers

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 Jul 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 Jul 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 Jul 2025, 20:40 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 20:10 UTC

Earnings

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 19:56 UTC

Earnings

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 Jul 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 Jul 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 Jul 2025, 19:01 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 Jul 2025, 17:38 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 Jul 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 Jul 2025, 17:13 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 16:46 UTC

Earnings

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 Jul 2025, 16:45 UTC

Earnings

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 Jul 2025, 16:27 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 Jul 2025, 16:02 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 Jul 2025, 15:34 UTC

Earnings

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 Jul 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 Jul 2025, 15:05 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 Jul 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 Jul 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 Jul 2025, 14:36 UTC

Market Talk
Earnings

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer Comparison

Price change

Iovance Biotherapeutics Inc Forecast

Price Target

By TipRanks

197.12% upside

12 Months Forecast

Average 9.3 USD  197.12%

High 25 USD

Low 1 USD

Based on 11 Wall Street analysts offering 12 month price targets forIovance Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

6

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

3.0208 / 3.5Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

145 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.